APA (7th ed.) Citation

Schneeweiss, A. (2019). Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. European journal of cancer, 106, . https://doi.org/10.1016/j.ejca.2018.10.015

Chicago Style (17th ed.) Citation

Schneeweiss, Andreas. "Intense Dose-dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (plus Carboplatin in Triple-negative Breast Cancer) for Neoadjuvant Treatment of High-risk Early Breast Cancer (GeparOcto-GBG 84): A Randomised Phase III Trial." European Journal of Cancer 106 (2019). https://doi.org/10.1016/j.ejca.2018.10.015.

MLA (9th ed.) Citation

Schneeweiss, Andreas. "Intense Dose-dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (plus Carboplatin in Triple-negative Breast Cancer) for Neoadjuvant Treatment of High-risk Early Breast Cancer (GeparOcto-GBG 84): A Randomised Phase III Trial." European Journal of Cancer, vol. 106, 2019, https://doi.org/10.1016/j.ejca.2018.10.015.